No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
PHAT240517C7500
- 2.90
- +1.30+81.25%
15min DelayClose May 14 15:59 ET
2.90High2.90Low
2.90Open1.60Pre Close10 Volume294 Open Interest7.50Strike Price2.90KTurnover0.00%IV-0.38%PremiumMay 17, 2024Expiry Date2.89Intrinsic Value100Multiplier2DDays to Expiry0.01Time Value100Contract SizeAmericanOptions Type--Delta--Gamma3.65Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- 1D
News
Craig-Hallum Remains a Buy on Phathom Pharmaceuticals (PHAT)
Express News | HC Wainwright & Co. Reiterates Buy on Phathom Pharmaceuticals, Maintains $28 Price Target
Phathom Pharmaceuticals | 10-Q: Quarterly report
Analysts Offer Insights on Healthcare Companies: Phathom Pharmaceuticals (PHAT), ACELYRIN, INC. (SLRN) and Moderna (MRNA)
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q1 Loss, Lags Revenue Estimates
Express News | Phathom Pharmaceuticals Inc - Believes It Will Have Sufficient Capital to Fund Operations Through End of 2026.
Comments
$Phathom Pharmaceuticals(PHAT.US$ NEWS
SynOx Therapeutics announces $75m Series B round to fund Phase 3 trial of potential best-in-class treatment for TGCT
SynOx Therapeutics has closed a $75m Series B financing round led by Forbion, HealthCap, and Bioqube Ventures to fund a Phase 3 trial of emactuzumab, a potential best-in-class treatment for Tenosynovial Giant Cell Tumour (TGCT). Emactuzumab has shown promising clinical activity with a 71% objective response rate and good tolerability in earl...
SynOx Therapeutics announces $75m Series B round to fund Phase 3 trial of potential best-in-class treatment for TGCT
SynOx Therapeutics has closed a $75m Series B financing round led by Forbion, HealthCap, and Bioqube Ventures to fund a Phase 3 trial of emactuzumab, a potential best-in-class treatment for Tenosynovial Giant Cell Tumour (TGCT). Emactuzumab has shown promising clinical activity with a 71% objective response rate and good tolerability in earl...
2
$Phathom Pharmaceuticals(PHAT.US$ a high potential share..vonoprazan is a lot more effective than other ppi.
Insider share sales at Phathom Pharmaceuticals in the last three months are not substantial but still concerning. The level of insider ownership shows some alignment with smaller shareholders. However, 6 warning signs, 3 of which are concerning, should be noted by investors.
$Phathom Pharmaceuticals(PHAT.US$ wonder if breakout will continue to run
Read more